NCT01215097 - Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy | Biotech Hunter

Enrollment

306

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Linagliptin

once a day

DRUG

placebo

once a day

Trial Locations (19)

1218.65.86007 Boehringer Ingelheim Investigational Site, Beijing

1218.65.86011 Boehringer Ingelheim Investigational Site, Chongqing

1218.65.86008 Boehringer Ingelheim Investigational Site, Dalian

1218.65.86010 Boehringer Ingelheim Investigational Site, Fuzhou

1218.65.86014 Boehringer Ingelheim Investigational Site, Hangzhou

1218.65.86005 Boehringer Ingelheim Investigational Site, Hefei

1218.65.86006 Boehringer Ingelheim Investigational Site, Hefei

1218.65.86012 Boehringer Ingelheim Investigational Site, Nanjing

1218.65.86001 Boehringer Ingelheim Investigational Site, Shanghai

1218.65.86002 Boehringer Ingelheim Investigational Site, Shanghai

1218.65.86003 Boehringer Ingelheim Investigational Site, Shanghai

1218.65.86004 Boehringer Ingelheim Investigational Site, Suzhou

1218.65.86015 Boehringer Ingelheim Investigational Site, Wenzhou

1218.65.86009 Boehringer Ingelheim Investigational Site, Wuhan

1218.65.86013 Boehringer Ingelheim Investigational Site, Yangzhou

1218.65.60002 Boehringer Ingelheim Investigational Site, Johor Bahru

1218.65.60001 Boehringer Ingelheim Investigational Site, Kelantan

1218.65.63001 Boehringer Ingelheim Investigational Site, Marikina City

1218.65.63002 Boehringer Ingelheim Investigational Site, San Juan City